Amgen

THOUSAND OAKS, Calif., May 16, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will participate in the UBS Global Life Sciences Conference on Tuesday, May 21, 2013, at the Sheraton New York Times Square in New York City, beginning at 10:00 a.m. Eastern Daylight Time. Joseph P. Miletich, M.D., Ph.D., ... read more

THOUSAND OAKS, Calif., May 15, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from three analyses of Vectibix(®) (panitumumab) in combination with FOLFOX, an oxaliplatin-based chemotherapy regimen, as a first-line treatment for metastatic colorectal cancer (mCRC). These analyses include the description of new predictive biomarkers of ... read more

THOUSAND OAKS, Calif., May 15, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will present data from several studies of both pipeline and marketed products at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting from May 31 to June 4 in Chicago. "The data that we are presenting ... read more

THOUSAND OAKS, Calif. and ZHEJIANG, China, May 9, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Zhejiang Beta Pharma Co., Ltd. (Zhejiang Beta Pharma) today announced that the companies have signed an agreement to form a joint venture to commercialize Amgen's Vectibix(®) (panitumumab) in the Chinese market. ... read more

THOUSAND OAKS, Calif., May 7, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Phase 3 head-to-head ASPECCT ('763) trial evaluating Vectibix(®) (panitumumab) versus Erbitux(®) (cetuximab) as a single agent for the treatment of chemorefractory metastatic colorectal cancer (mCRC) in patients with wild-type KRAS tumors (n=1,010) met its primary endpoint ... read more

THOUSAND OAKS, Calif., May 1, 2013 /PRNewswire/ -- Amgen today announced that four individuals who are an inspiration and have made a difference for others affected by cancer have been selected as Breakaway from Cancer(®) Champions. They will be honored as part of Amgen's Breakaway from Cancer initiative at the ... read more

THOUSAND OAKS, Calif., April 23, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2013. Key results for the quarter include: -- Total revenues increased 5 percent to $4,238 million, with 6 percent ... read more

THOUSAND OAKS, Calif., April 18, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its first quarter financial results on Tuesday, April 23, 2013, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community ... read more

THOUSAND OAKS, Calif., March 19, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced top-line results from the Phase 3 trial in melanoma, which evaluated the efficacy and safety of talimogene laherparepvec for the treatment of unresected stage IIIB, IIIC or IV melanoma compared to treatment with subcutaneous ... read more

THOUSAND OAKS, Calif., March 6, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) announced that its Board of Directors today declared a $0.47 per share dividend for the second quarter of 2013. The dividend will be paid on June 7, 2013, to all stockholders of record as of the close ... read more

THOUSAND OAKS, Calif., March 1, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Cowen and Company 33(rd )Annual Health Care Conference on Wednesday, March 6, 2013, at the Boston Marriott Copley Place, Boston, Mass., beginning at 9:20 a.m. EST. Arvind Sood, vice president of Investor ... read more

THOUSAND OAKS, Calif., Feb. 22, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) notes that an analysis by the Congressional Budget Office released this week shows that, contrary to the implications of past media reports, keeping oral-only drugs in Medicare Part D would actually achieve significant savings over time for ... read more

THOUSAND OAKS, Calif., Feb. 8, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the call for nominations for Breakaway from Cancer(® )Champions. For the last five years, Amgen has recognized outstanding individuals making a difference for cancer patients and their loved ones in communities across California ... read more

NEW YORK, Feb. 7, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today outlined the company's long-term strategy during a Business Review meeting with analysts and investors in New York City. Robert A. Bradway, chairman and chief executive officer at Amgen, opened the meeting by affirming the company's core strategy will continue to focus ... read more

THOUSAND OAKS, Calif., Jan. 31, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will hold its Business Review Meeting on Thursday, Feb. 7, 2013, at the Mandarin Oriental Hotel, 80 Columbus Circle, New York City, beginning at 8 a.m. Eastern Standard Time. In the meeting, Robert ... read more

THOUSAND OAKS, Calif., Jan. 26, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) announced today results from Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES), a Phase 3 trial which evaluated Neulasta(® )(pegfilgrastim) in 845 patients receiving FOLFOX or FOLFIRI and bevacizumab for the first-line treatment of locally-advanced or metastatic colorectal ... read more

THOUSAND OAKS, Calif., Jan. 25, 2013 /PRNewswire/ -- In conjunction with our oncology biosimilars partner Actavis' announcement earlier today of our four oncology biosimilars products, Amgen (NASDAQ:AMGN) today stated that it supports state biosimilars initiatives that focus on sound science and patient safety. As a biotech ... read more

THOUSAND OAKS, Calif., Jan. 23, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2012. Key results include: -- For the full year, total revenues increased 11 percent to $17,265 million, ... read more

THOUSAND OAKS, Calif., Jan. 18, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2012 financial results on Wednesday, Jan. 23, 2013, after the close of the financial markets. The announcement will be followed by a conference call with ... read more

THOUSAND OAKS, Calif., Jan. 16, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced top-line results of the Phase 3 Aranesp(®) (darbepoetin alfa) RED-HF(®) (Reduction of Events With Darbepoetin Alfa in Heart Failure) Trial. The trial was initiated in 2006, and a total of 2,278 patients with symptomatic systolic heart failure ... read more